먹튀없는 바카라사이트 아톰카지노 and MMV form a partnership to co-develop next-generation mRNA-NanoMab malaria vaccine

[by Ji, Yong Jun] Shaperon announced on October 29 that it has entered into a strategic research collaboration with the Swiss non-profit organization Medicines for Malaria Venture (MMV) to develop a novel long-acting nanobody-based antimalarial therapy. The partnership was established following MMV’s recognition of Shaperon's NanoMab technology as a groundbreaking innovation platform.

The project seeks to develop an antimalarial product that can be rapidly mass-produced and globally distributed, including to developing markets, by combining 먹튀없는 바카라사이트 아톰카지노's proprietary NanoMab platform with the molecular simplicity of nanobodies and the efficient delivery properties of messenger ribonucleic acid (mRNA) technology.

The two companies are co-먹튀없는 바카라사이트 아톰카지노ing a NanoMab designed to simultaneously target multiple malaria parasite antigens, as well as individual antigen targets. This approach is expected to enable simultaneous therapeutic effects across multiple stages of the malaria life cycle.

먹튀없는 바카라사이트 아톰카지노 is a Swiss non-profit organization dedicated to the discovery, development, and delivery of accessible new antimalarial drugs for the treatment, prevention, and eradication of malaria. Since its establishment in 1999, 먹튀없는 바카라사이트 아톰카지노 has been at the forefront of global malaria research, spearheading efforts to expand existing therapeutic options and driving innovation by addressing critical gaps in research, development, and accessibility.

먹튀없는 바카라사이트 아톰카지노 plans to leverage MMV's extensive global network, expertise, and resources to develop a single-dose, easily storable mRNA-based NanoMab passive vaccine suitable for deployment in developing countries. MMV, in turn, intends to utilize a range of non-dilutive financial resources to support this strategic research collaboration, actively facilitating the clinical development and eventual commercialization of the candidate molecules.

"As a technology spinoff from Seoul National University's technology startup, support from global health organizations such as MMV is crucial to advancing our R&D initiatives. This collaboration is particularly meaningful as it enables us to secure funding without equity dilution. It marks a turning point for our company, positioning Shaperon as a global leader in nanobody-based solutions for infectious diseases," a Shaperon official stated.

Meanwhile, 먹튀없는 바카라사이트 아톰카지노's flagship NanoMab program is an mRNA-based PD-L1 target currently in the preclinical stage. The program has successfully demonstrated in vivo expression and therapeutic blood concentrations.